专利检索 ap:("ORYZON GENOMICS, S.A.") AND inv:"Marc Martinell Pedemonte" 第 1 页

1.

发明申请
LYSINE DEMETHYLASE INHIBITORS FOR MYELOPROLIFERATIVE DISORDERS 有权

公开(公告)号：US20150232436A1

公开(公告)日：2015-08-20

申请号：US14184745

申请日：2014-02-20

申请人： Oryzon Genomics S.A.

发明人： Jonathan Alleman Baker , Julio Castro Palomino , Matthew Colin Thor Fyfe , Tamara Maes , Marc Martinell Pedemonte

IPC分类号： C07D295/195 , A61K31/164 , A61K31/495 , C07D213/38 , A61K31/4418 , A61K45/06 , A61K31/40 , C07C215/64 , A61K31/135 , C07C311/32 , A61K31/18 , C07C237/20 , C07D207/14

CPC分类号： C07D295/195 , A61K31/00 , A61K31/131 , A61K31/135 , A61K31/138 , A61K31/15 , A61K31/164 , A61K31/18 , A61K31/40 , A61K31/4418 , A61K31/495 , A61K45/06 , C07D207/14 , C07D213/38

摘要： The invention relates to methods and compositions for the treatment or prevention of diseases and disorders associated with myeloproliferative disorders. In particular, the invention relates to an LSD 1 inhibitor for use in treating or preventing Philadelphia chromosome negative myeloproliferative disorders.

摘要翻译： 本发明涉及用于治疗或预防与骨髓增生性疾病相关的疾病和病症的方法和组合物。特别地，本发明涉及用于治疗或预防费城染色体阴性骨髓增生性疾病的LSD1抑制剂。

2.

发明申请
(HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS 有权
标题翻译：（HETERO）ARYL CYPOPRAMLAMINE COMPOUNDS AS LSD1 INHIBITORS

公开(公告)号：US20150025054A1

公开(公告)日：2015-01-22

申请号：US14352711

申请日：2012-10-22

申请人： ORYZON GENOMICS, S.A.

发明人： Alberto Ortega Muñoz , Matthew Colin Thor Fyfe , Marc Martinell Pedemonte , Maria de los Angeles Estirate Martínez , Nuria Valls Vidal , Guido Kurz , Julio Cesar Castro Palomino Lar

IPC分类号： C07D451/04 , C07D405/12 , C07D309/04 , C07D223/12 , C07D205/04 , C07D221/20 , C07D215/42 , C07D401/12 , C07D211/58 , C07D207/14

CPC分类号： C07D211/58 , C07D205/04 , C07D207/09 , C07D207/14 , C07D209/96 , C07D211/26 , C07D211/56 , C07D215/42 , C07D221/20 , C07D223/12 , C07D309/04 , C07D309/14 , C07D335/02 , C07D401/04 , C07D401/12 , C07D405/12 , C07D417/12 , C07D451/04

摘要： The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula I as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.

摘要翻译： 本发明涉及（异）芳基环丙胺化合物，特别包括本文所述和定义的式I化合物及其在治疗中的用途，包括例如治疗或预防癌症，神经疾病或病症，或病毒感染。

3.

发明申请
(HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS 审中-公开

公开(公告)号：US20180079709A1

公开(公告)日：2018-03-22

申请号：US15497556

申请日：2017-04-26

申请人： Oryzon Genomics S.A.

发明人： Alberto ORTEGA MUÑOZ , Matthew Colin Thor Fyfe , Marc Martinell Pedemonte , Maria de los Àngeles Estiarte Martinez , Nuria Valls Vidal , Guido Kurz , Julio Cesar Castro Palomino Laria

IPC分类号： C07C211/36 , C07D333/20 , C07C273/00 , C07D213/57 , C07D213/73 , C07D231/56 , C07C213/00 , C07C215/64 , C07C217/74 , C07C211/40 , C07C217/54 , C07C215/46 , C07C311/21 , C07C311/08 , C07C273/18 , C07C209/28 , C07C211/38 , C07C269/00 , C07D213/74 , C07D307/52 , C07D213/38 , C07D213/30 , C07D295/26 , C07D295/135 , C07D295/096 , C07D277/28 , C07D207/14 , C07D231/12 , C07C275/26 , C07C271/24

CPC分类号： C07C211/36 , C07B2200/07 , C07C209/28 , C07C211/37 , C07C211/38 , C07C211/40 , C07C213/00 , C07C215/46 , C07C215/64 , C07C217/54 , C07C217/74 , C07C269/00 , C07C271/24 , C07C273/00 , C07C273/18 , C07C275/26 , C07C311/08 , C07C311/21 , C07C2601/02 , C07C2601/04 , C07C2601/14 , C07C2602/08 , C07D207/14 , C07D213/30 , C07D213/38 , C07D213/57 , C07D213/73 , C07D213/74 , C07D231/12 , C07D231/56 , C07D277/28 , C07D295/096 , C07D295/135 , C07D295/26 , C07D307/52 , C07D333/20

摘要： The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.

4.

发明授权
Cyclopropylamine derivatives useful as LSD1 inhibitors 有权

公开(公告)号：US09676701B2

公开(公告)日：2017-06-13

申请号：US14640395

申请日：2015-03-06

申请人： Oryzon Genomics, S.A.

发明人： Matthew Colin Thor Fyfe , Alberto Ortega Muñoz , Julio Castro-Palomino Laria , Marc Martinell Pedemonte , Maria de los Angeles Estiarte-Martinez , Nuria Valls Vidal

IPC分类号： C07C211/40 , C07C215/64 , C07C217/64 , C07C217/74 , C07C255/53 , C07C255/54 , C07C311/08 , C07C311/09 , C07C311/21 , C07D213/38 , C07D213/40 , C07D213/42 , C07D213/56 , C07D213/57 , C07D239/26 , C07D277/28 , C07D333/20 , C07D401/04 , C07D405/04 , C07D409/04 , C07C255/59 , C07D213/64 , C07D401/10 , C07D405/10 , C07D409/10

CPC分类号： C07C211/40 , C07B2200/07 , C07C215/64 , C07C217/74 , C07C255/53 , C07C255/54 , C07C255/59 , C07C311/08 , C07C311/09 , C07C311/21 , C07C2601/02 , C07D213/38 , C07D213/40 , C07D213/42 , C07D213/56 , C07D213/57 , C07D213/64 , C07D239/26 , C07D277/28 , C07D333/20 , C07D401/04 , C07D401/10 , C07D405/04 , C07D405/10 , C07D409/04 , C07D409/10

摘要： The invention relates to cyclopropylamine compounds, in particular the compounds of Formula (I), and their use in therapy, including e.g. in the treatment or prevention of cancer, a neurological disease or condition, or viral infection.

5.

发明申请
CYCLOPROPYLAMINE INHIBITORS OF OXIDASES 审中-公开

公开(公告)号：US20160000768A1

公开(公告)日：2016-01-07

申请号：US14711156

申请日：2015-05-13

申请人： Oryzon Genomics S.A.

发明人： Julio Castro-Palomino Laria , Matthew Colin Thor Fyfe , Marc Martinell Pedemonte , Alberto Ortega Muñoz , Núria Valls Vidal

IPC分类号： A61K31/4439 , A61K31/166 , A61K31/277 , A61K31/4418 , A61K31/136

CPC分类号： A61K31/4439 , A61K31/136 , A61K31/166 , A61K31/277 , A61K31/4418 , C07C211/52 , C07C211/53 , C07C211/55 , C07C211/56 , C07C217/92 , C07C237/30 , C07C255/58 , C07D213/74 , C07D401/12

摘要： The invention relates to cyclopropylamine compounds, in particular the compounds of Formula (I) as described and defined herein, and their use in therapy, including, e.g., the treatment or prevention of cancer.

6.

发明申请
(HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS 有权
标题翻译：（HETERO）ARYL CYPOPRAMLAMINE COMPOUNDS AS LSD1 INHIBITORS

公开(公告)号：US20140256729A1

公开(公告)日：2014-09-11

申请号：US14352719

申请日：2012-10-22

申请人： ORYZON GENOMICS, S.A.

发明人： Alberto Ortega Muñoz , Matthew Colin Thor Fyfe , Marc Martinell Pedemonte , Maria de los Ángeles Estiarte Martínez , Nuria Valls Vidal , Guido Kurz , Julio Cesar Castro Palomino Laria

IPC分类号： C07C211/36 , C07C209/28 , C07D295/135 , C07D213/38 , C07C275/26 , C07D207/14 , C07C271/24 , C07C273/18 , C07C211/38 , C07C269/00 , C07D277/28

CPC分类号： C07C211/36 , C07B2200/07 , C07C209/28 , C07C211/37 , C07C211/38 , C07C211/40 , C07C213/00 , C07C215/46 , C07C215/64 , C07C217/54 , C07C217/74 , C07C269/00 , C07C271/24 , C07C273/00 , C07C273/18 , C07C275/26 , C07C311/08 , C07C311/21 , C07C2601/02 , C07C2601/04 , C07C2601/14 , C07C2602/08 , C07D207/14 , C07D213/30 , C07D213/38 , C07D213/57 , C07D213/73 , C07D213/74 , C07D231/12 , C07D231/56 , C07D277/28 , C07D295/096 , C07D295/135 , C07D295/26 , C07D307/52 , C07D333/20

摘要： The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and theft use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.

摘要翻译： 本发明涉及（异）芳基环丙胺化合物，特别包括本文所述和定义的式（I）化合物和治疗中的盗窃用途，包括例如治疗或预防癌症，神经疾病或病症，或病毒感染。

7.

发明授权
Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use 有权

公开(公告)号：US10233178B2

公开(公告)日：2019-03-19

申请号：US15623866

申请日：2017-06-15

申请人： Oryzon Genomics S.A.

发明人： Alberto Ortega Muñoz , Matthew Colin Thor Fyfe , Marc Martinell Pedemonte , Iñigo Tirapu Fernandez De La Cuesta , Maria de los Ángeles Estiarte Martinez

IPC分类号： A61K31/505 , A61K31/44 , C07D417/12 , A61K31/433 , A61K31/4245 , A61K31/422 , A61K31/506 , A61K31/4439 , C07D213/73 , C07D237/20 , C07D239/42 , C07D241/20 , C07D253/07 , C07D261/14 , C07D263/48 , C07D271/07 , C07D271/113 , C07D277/40 , C07D285/12 , C07D401/12 , C07D413/12 , C07D285/135 , C07D285/08

摘要： The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. Thus, in one specific aspect the invention relates to formulas (II), (III), (IV), (V), (VI), (VII), (VIII), (IX).